靶向治疗术后结膜:沉默SPARC减少胶原沉积
该研究在小鼠结膜瘢痕模型中,将负载Sparc siRNA的层层自组装纳米颗粒术后立即注入结膜,评估其减少SPARC表达和纤维化的效果。结果显示siSparc显著抑制Sparc转录,并降低Col1a1、Fn1、Mmp14 mRNA及SPARC和COL1A1蛋白水平,未见明显组织反应或凋亡。提示靶向SPARC治疗青光眼术后结膜纤维化安全可行。
要点
- siSparc纳米颗粒可显著抑制小鼠术后结膜Sparc转录。
- SPARC沉默伴随Col1a1、Fn1、Mmp14 mRNA及COL1A1蛋白降低。
- 未见明显组织反应或凋亡,支持靶向治疗安全性。
核心结论
- 靶向SPARC治疗有效减少手术小鼠结膜的SPARC和胶原产生。
- 该概念验证研究提示青光眼手术纤维化靶向治疗安全可行,并可能扩展至其他纤维化相关基因。
研究设计与样本
- 采用小鼠结膜瘢痕模型进行实验性手术。
- 术后立即将负载scrambled或Sparc siRNA的层层自组装纳米颗粒注入结膜。
主要发现
- siSparc在术后第7天和第14天分别使Sparc转录抑制2.04倍和1.39倍。
- 第7天Sparc抑制伴随Col1a1(2.52倍)、Fn1(2.89倍)和Mmp14(2.23倍)mRNA显著减少。
- 蛋白水平上,siSparc治疗在两个时间点均显著降低SPARC和COL1A1。
- 共聚焦显微镜可见纳米颗粒位于细胞样结构内,未观察到明显组织反应或凋亡。
临床怎么用
- 为青光眼滤过术后抗纤维化提供潜在靶向策略,但尚需临床研究验证。
局限性
- 研究为小鼠模型的概念验证,结论外推至人类需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To develop targeted antifibrotic therapy for glaucoma filtration surgery; this study determines the effectiveness of small interfering RNA (siRNA) to reduce in vivo secreted protein acidic and rich in cysteine (SPARC) expression using the mouse model of conjunctival scarring. METHODS: Experimental surgery was performed as described for the mouse model of conjunctival scarring. Scrambled (siScram) or Sparc (siSparc) siRNAs, loaded on layer-by-layer (LbL) nanoparticles, were injected into the conjunctiva immediately after surgery. Expression of Sparc, Col1a1, Fn1 and Mmp14 was measured by real-time PCR and immunoblotting on days 7 and 14 postsurgery. Live imaging of the operated eyes was performed using slit lamp, anterior segment-optical coherence tomography and confocal microscopy. Tissue pathology was evaluated by histochemical and immunofluorescent analyses of operated conjunctival cryosections. Tissue apoptosis was quantitated by annexin V assay. RESULTS : siSparc, delivered via expanded LbL nanoparticles, significantly inhibited Sparc transcription in both day 7 (2.04-fold) and day 14 (1.39-fold) treated tissues. Sparc suppression on day 7 was associated with a significant reduction of Col1a1 (2.52-fold), Fn1 (2.89-fold) and Mmp14 (2.23-fold) mRNAs. At the protein level, both SPARC and collagen 1A1 (COL1A1) were significantly reduced at both time points with siSparc treatment. Nanoparticles were visualised within cell-like structures by confocal microscopy, while overt tissue response or apoptosis was not observed. CONCLUSIONS : SPARC targeted therapy effectively reduced both SPARC and collagen production in the operated mouse conjunctiva. This proof-of-concept study suggests that targeted treatment of fibrosis in glaucoma surgery is safe and feasible, with the potential to extend to a range of potential genes associated with fibrosis.
引用
- Seet LF, Tan YF, Toh LZ, et al. Targeted therapy for the post-operative conjunctiva: SPARC silencing reduces collagen deposition. Br J Ophthalmol. 2018. PMID: 30021812. doi:10.1136/bjophthalmol-2018-311937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。